137 related articles for article (PubMed ID: 34280914)
1. Targeting acute myeloid leukemia cells by CD33 receptor-specific MoS
Štefík P; Annušová A; Lakatoš B; Elefantová K; Čepcová L; Hofbauerová M; Kálosi A; Jergel M; Majková E; Šiffalovič P
Biomed Mater; 2021 Aug; 16(5):. PubMed ID: 34280914
[TBL] [Abstract][Full Text] [Related]
2. Selection of resistant acute myeloid leukemia SKM-1 and MOLM-13 cells by vincristine-, mitoxantrone- and lenalidomide-induced upregulation of P-glycoprotein activity and downregulation of CD33 cell surface exposure.
Imrichova D; Messingerova L; Seres M; Kavcova H; Pavlikova L; Coculova M; Breier A; Sulova Z
Eur J Pharm Sci; 2015 Sep; 77():29-39. PubMed ID: 26002042
[TBL] [Abstract][Full Text] [Related]
3. Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy.
Niu F; Yan J; Ma B; Li S; Shao Y; He P; Zhang W; He W; Ma PX; Lu W
Biomaterials; 2018 Jun; 167():132-142. PubMed ID: 29571049
[TBL] [Abstract][Full Text] [Related]
4. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
[TBL] [Abstract][Full Text] [Related]
5. ImmunoPET, [
Srideshikan SM; Brooks J; Zuro D; Kumar B; Sanchez J; Echavarria Parra L; Orellana M; Vishwasrao P; Nair I; Chea J; Poku K; Bowles N; Miller A; Ebner T; Molnar J; Rosenthal J; Vallera DA; Wong JYC; Stein AS; Colcher D; Shively JE; Yazaki PJ; Hui SK
Clin Cancer Res; 2019 Dec; 25(24):7463-7474. PubMed ID: 31548348
[TBL] [Abstract][Full Text] [Related]
6. CD123/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape.
Sun S; Zou H; Li L; Liu Q; Ding N; Zeng L; Li H; Mao S
Int J Pharm; 2019 Sep; 568():118518. PubMed ID: 31319147
[TBL] [Abstract][Full Text] [Related]
7. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.
van Der Velden VH; te Marvelde JG; Hoogeveen PG; Bernstein ID; Houtsmuller AB; Berger MS; van Dongen JJ
Blood; 2001 May; 97(10):3197-204. PubMed ID: 11342449
[TBL] [Abstract][Full Text] [Related]
8. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.
Kenderian SS; Ruella M; Shestova O; Klichinsky M; Aikawa V; Morrissette JJ; Scholler J; Song D; Porter DL; Carroll M; June CH; Gill S
Leukemia; 2015 Aug; 29(8):1637-47. PubMed ID: 25721896
[TBL] [Abstract][Full Text] [Related]
9. Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms.
Gbadamosi MO; Shastri VM; Hylkema T; Papageorgiou I; Pardo L; Cogle CR; Doty A; Loken MR; Meshinchi S; Lamba JK
Future Oncol; 2021 Jan; 17(3):263-277. PubMed ID: 33356566
[TBL] [Abstract][Full Text] [Related]
10. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
[TBL] [Abstract][Full Text] [Related]
11. Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.
Laszlo GS; Harrington KH; Gudgeon CJ; Beddoe ME; Fitzgibbon MP; Ries RE; Lamba JK; McIntosh MW; Meshinchi S; Walter RB
Oncotarget; 2016 Jul; 7(28):43281-43294. PubMed ID: 27248327
[TBL] [Abstract][Full Text] [Related]
12. CD33 expression on natural killer cells is a potential confounder for residual disease detection in acute myeloid leukemia by flow cytometry.
Eckel AM; Cherian S; Miller V; Soma L
Cytometry B Clin Cytom; 2020 Mar; 98(2):174-178. PubMed ID: 31622025
[TBL] [Abstract][Full Text] [Related]
13. Targeting CD33 for acute myeloid leukemia therapy.
Liu J; Tong J; Yang H
BMC Cancer; 2022 Jan; 22(1):24. PubMed ID: 34980040
[TBL] [Abstract][Full Text] [Related]
14. The past and future of CD33 as therapeutic target in acute myeloid leukemia.
Laszlo GS; Estey EH; Walter RB
Blood Rev; 2014 Jul; 28(4):143-53. PubMed ID: 24809231
[TBL] [Abstract][Full Text] [Related]
15. In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia.
Hagemann UB; Wickstroem K; Wang E; Shea AO; Sponheim K; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS
Mol Cancer Ther; 2016 Oct; 15(10):2422-2431. PubMed ID: 27535972
[TBL] [Abstract][Full Text] [Related]
16. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
Jitschin R; Saul D; Braun M; Tohumeken S; Völkl S; Kischel R; Lutteropp M; Dos Santos C; Mackensen A; Mougiakakos D
J Immunother Cancer; 2018 Nov; 6(1):116. PubMed ID: 30396365
[TBL] [Abstract][Full Text] [Related]
17. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
Laszlo GS; Gudgeon CJ; Harrington KH; Dell'Aringa J; Newhall KJ; Means GD; Sinclair AM; Kischel R; Frankel SR; Walter RB
Blood; 2014 Jan; 123(4):554-61. PubMed ID: 24311721
[TBL] [Abstract][Full Text] [Related]
18. An insight into the dual role of MoS2-based nanocarriers in anticancer drug delivery and therapy.
Ghosh S; Lai JY
Acta Biomater; 2024 Apr; 179():36-60. PubMed ID: 38552760
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia fusion genes can be found in CD33-negative cells.
Chen Y; Liu Q; Xing H; Rao Q; Wang M; Mi Y; Wei H; Wang J
Int J Lab Hematol; 2022 Dec; 44(6):1111-1114. PubMed ID: 35915999
[TBL] [Abstract][Full Text] [Related]
20. Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33.
Romão E; Krasniqi A; Maes L; Vandenbrande C; Sterckx YG; Stijlemans B; Vincke C; Devoogdt N; Muyldermans S
Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31906437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
